A genomics-based classification of human lung tumors

Science Translational Medicine

Volumn 5, Issue 209, 2013, Pages

  Seidel, Danila ^a   Zander, Thomas ^a,af   Heukamp, Lukas C ^a,af   Peifer, Martin ^a   Bos, Marc ^a,af   Fernández Cuesta, Lynnette ^a   Leenders, Frauke ^a   Lu, Xin ^a   Ansén, Sascha ^a   Gardizi, Masyar ^a,af   Nguyen, Chau ^a   Berg, Johannes ^a   Russell, Prudence ^ab   Wainer, Zoe ^aa   Schildhaus, Hans Ulrich ^a,af,az   Rogers, Toni Maree ^d   Solomon, Benjamin ^d   Pao, William ^w   Carter, Scott L ^z   Getz, Gad ^z   Hayes, D Neil ^ae   Wilkerson, Matthew D ^ae,ba   Thunnissen, Erik ^k   Travis, William D ^l   Perner, Sven ^e   Wright, Gavin ^d,aa   Brambilla, Elisabeth ^s,u,v   Büttner, Reinhard ^a,af   Wolf, Jürgen ^a,af   Thomas, Roman K ^a,af   Gabler, Franziska ^a,b   Wilkening, Ines ^b   Müller, Christian ^a   Dahmen, Ilona ^a   Menon, Roopika ^e   König, Katharina ^a,af   Albus, Kerstin ^a,af   Merkelbach Bruse, Sabine ^a,af   Fassunke, Jana ^a,af   Schmitz, Katja ^a,af   Kuenstlinger, Helen ^a,af   Kleine, Michaela A ^a,af   Binot, Elke ^a,af   Querings, Silvia ^a,b   Altmüller, Janine ^a,b   Bäßmann, Ingelore ^b   Nürnberg, Peter ^a,b   Schneider, Peter M ^a   Bogus, Magdalena ^a   Soltermann, Alex ^r   Moch, Holger ^r   Brustugun, Odd Terje ^p,q   Solberg, Steinar ^p   Lund Iversen, Marius ^p   Helland, Åslaug ^p,q   Muley, Thomas ^h,ad   Hoffmann, Hans ^h   Schnabel, Philipp A ^g,ad   Chen, Yuan ^f   Groen, Harry ^j   Timens, Wim ^j   Sietsma, Hannie ^j   Clement, Joachim H ^f   Weder, Walter ^r   Sänger, Jörg ⁱ   Stoelben, Erich ^c   Ludwig, Corinna ^c   Engel Riedel, Walburga ^c   Smit, Egbert ^k   Heideman, Daniëlle A M ^k   Snijders, Peter J F ^k   Nogova, Lucia ^a,af   Sos, Martin L ^a,af,ag   Mattonet, Christian ^a,af   Töpelt, Karin ^a,af   Scheffler, Matthias ^a,af   Goekkurt, Eray ^af,ai   Kappes, Rainer ^af,aj,ap   Krüger, Stefan ^af,aj   Kambartel, Kato ^af,ak   Behringer, Dirk ^af,al,am   Schulte, Wolfgang ^y,af   Galetke, Wolfgang ^af,an   Randerath, Winfried ^af,ao   Heldwein, Matthias ^af   Schlesinger, Andreas ^af,aq   Serke, Monika ^af,ar   Hekmat, Khosro ^af   Frank, Konrad F ^af   Schnell, Roland ^af,as   Reiser, Marcel ^af,at   Hünerlitürkoglu, Ali Nuri ^af,au   Schmitz, Stephan ^af,av   Meffert, Lisa ^x,af   Ko, Yon Dschun ^x,af   Litt Lampe, Markus ^af,aw   Gerigk, Ulrich ^y,af   Fricke, Rainer ^ah   Besse, Benjamin ^s   Brambilla, Christian ^u,v   Lantuejoul, Sylvie ^s,ay   Lorimier, Philippe ^s   Moro Sibilot, Denis ^u,v   Cappuzzo, Federico ^m   Ligorio, Claudia ⁿ   Damiani, Stefania ⁿ   Field, John K ^o   Hyde, Russell ^o   Validire, Pierre ^t   Girard, Philippe ^t   Muscarella, Lucia A ^ac   Fazio, Vito M ^ac,ax   Hallek, Michael ^a   Soria, Jean Charles ^s   Achter, Viktor ^a   Lang, Ulrich ^a   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c KLINIKEN DER STADT KÖLN GGMBH   (Germany)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f JENA UNIVERSITY HOSPITAL   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ Institute for Pathology Bad Berka   (Germany)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m Ospedale Civile   (Italy)

ⁿ UNIVERSITY OF BOLOGNA   (Italy)

^o UNIVERSITY OF LIVERPOOL   (United Kingdom)

^p OSLO UNIVERSITY HOSPITAL   (Norway)

^q UNIVERSITY OF OSLO   (Norway)

^r UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^s INSTITUT GUSTAVE ROUSSY   (France)

^t INSTITUT MUTUALISTE MONTSOURIS   (France)

^u GRENOBLE UNIVERSITY HOSPITAL   (France)

^v INSERM   (France)

^w VANDERBILT INGRAM CANCER CENTER   (United States)

^x Klinik für Internistische Onkologie Evangelische Kliniken Bonn   (Germany)

^y Malteser Krankenhaus   (Germany)

^z BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^aa UNIVERSITY OF MELBOURNE   (Australia)

^ab ST VINCENT S HOSPITAL   (Australia)

^ac CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^ad Member of the German Center for Lung Research   (Germany)

^ae UNIVERSITY OF NORTH CAROLINA   (United States)

^af UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^ag UNIVERSITY OF CALIFORNIA   (United States)

^ah Epidemiologisches Krebsregister NRW   (Germany)

^ai Onkologische Schwerpunktpraxis Eppendorf   (Germany)

^aj Florence Nightingale Krankenhaus   (Germany)

^ak Krankenhaus Bethanien   (Germany)

^al Department of Anesthesiology   (Germany)

^am Lungenkrebszentrum Herne   (Germany)

^an Krankenhaus der Augustinerinnen   (Germany)

^ao Krankenhaus Bethanien Solingen   (Germany)

^ap Allergologie   (Germany)

^aq Evangelisches Krankenhaus Kalk   (Germany)

^ar LUNGENKLINIK HEMER   (Germany)

^as Praxis Internistische Onkologie und Hämatologie   (Germany)

^at Pioh Köln Zentrum   (Germany)

^au Lukaskrankenhaus GmbH   (Germany)

^av Gemeinschaftspraxis für Hämatologie und Onkologie Köln   (Germany)

^aw Division of Cardiovascular Medicine   (Germany)

^ax UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^ay INSTITUT ALBERT BONNIOT   (France)

^az UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^ba UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PLATINUM COMPLEX;

ADULT; AGED; ALK GENE; ARTICLE; CARCINOID; CONTROLLED STUDY; COPY NUMBER VARIATION; EGFR GENE; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENOMICS; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTO ONCOGENE; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL PREDICTION; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE; VERY ELDERLY; YOUNG ADULT;

EID: 84890046280     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006802     Document Type: Article

References (62)

1. W. Travis, E. Brambilla, H. Mueller-Hermelink, C. Harris, World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart (World Health Organization, Geneva, 2004).
2. W. D. Travis, E. Brambilla, M. Noguchi, A. G. Nicholson, K. Geisinger, Y. Yatabe, C. A. Powell, D. Beer, G. Riely, K. Garg, J. H. Austin, V. W. Rusch, F. R. Hirsch, J. Jett, P. C. Yang, M. Gould, American Thoracic Society, International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society: International multidisciplinary classification of lung adenocarcinoma: Executive summary. Proc. Am. Thorac. Soc. 8, 381-385 (2011).
3. T. J. Lynch, D. W.Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B. W. Brannigan, P. L.Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman, D. A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
4. J. G. Paez, P. A. Jänne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson, M. Meyerson, EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
5. W. Pao, N. Girard, New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12, 175-180 (2011).
6. S. Rodenhuis, R. J. Slebos, A. J. Boot, S. G. Evers, W. J.Mooi, S. S. Wagenaar, P. C. van Bodegom, J. L. Bos, Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 48, 5738-5741 (1988).
7. M. Soda, Y. L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, S. Fujiwara, H. Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, H. Mano, Identification of the transforming EML4-ALK fusion gene in nonsmall- cell lung cancer. Nature 448, 561-566 (2007).
8. A. J. Bass, H. Watanabe, C. H. Mermel, S. Yu, S. Perner, R. G. Verhaak, S. Y. Kim, L. Wardwell, P. Tamayo, I. Gat-Viks, A. H. Ramos, M. S. Woo, B. A. Weir, G. Getz, R. Beroukhim, M. O'Kelly, A. Dutt, O. Rozenblatt-Rosen, P. Dziunycz, J. Komisarof, L. R. Chirieac, C. J. Lafargue, V. Scheble, T. Wilbertz, C. Ma, S. Rao, H. Nakagawa, D. B. Stairs, L. Lin, T. J. Giordano, P.Wagner, J. D. Minna, A. F. Gazdar, C. Q. Zhu, M. S. Brose, I. Cecconello, U. Ribeiro Jr., S. K. Marie, O. Dahl, R. A. Shivdasani, M. S. Tsao, M. A. Rubin, K. K. Wong, A. Regev, W. C. Hahn, D. G. Beer, A. K. Rustgi, M. Meyerson, SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 41, 1238-1242 (2009).
9. P. S. Hammerman, M. L. Sos, A. H. Ramos, C. Xu, A. Dutt, W. Zhou, L. E. Brace, B. A. Woods, W. Lin, J. Zhang, X. Deng, S. M. Lim, S. Heynck, M. Peifer, J. R. Simard, M. S. Lawrence, R. C. Onofrio, H. B. Salvesen, D. Seidel, T. Zander, J. M. Heuckmann, A. Soltermann, H. Moch, M. Koker, F. Leenders, F. Gabler, S. Querings, S. Ansén, E. Brambilla, C. Brambilla, P. Lorimier, O. T. Brustugun, A. Helland, I. Petersen, J. H. Clement, H. Groen, W. Timens, H. Sietsma, E. Stoelben, J. Wolf, D. G. Beer, M. S. Tsao, M. Hanna, C. Hatton, M. J. Eck, P. A. Janne, B. E. Johnson, W. Winckler, H. Greulich, A. J. Bass, J. Cho, D. Rauh, N. S. Gray, K. K. Wong, E. B. Haura, R. K. Thomas, M. Meyerson, Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 1, 78-89 (2011).
10. A. Dutt, A. H. Ramos, P. S. Hammerman, C. Mermel, J. Cho, T. Sharifnia, A. Chande, K. E. Tanaka, N. Stransky, H. Greulich, N. S. Gray, M. Meyerson, Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 6, e20351 (2011).
11. J. Weiss, M. L. Sos, D. Seidel, M. Peifer, T. Zander, J. M. Heuckmann, R. T. Ullrich, R. Menon, S. Maier, A. Soltermann, H. Moch, P. Wagener, F. Fischer, S. Heynck, M. Koker, J. Schöttle, F. Leenders, F. Gabler, I. Dabow, S. Querings, L. C. Heukamp, H. Balke-Want, S. Ansén, D. Rauh, I. Baessmann, J. Altmüller, Z. Wainer, M. Conron, G. Wright, P. Russell, B. Solomon, E. Brambilla, C. Brambilla, P. Lorimier, S. Sollberg, O. T. Brustugun, W. Engel-Riedel, C. Ludwig, I. Petersen, J. Sänger, J. Clement, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D. Heideman, F. Cappuzzo, C. Ligorio, S. Damiani, M. Hallek, R. Beroukhim, W. Pao, B. Klebl, M. Baumann, R. Buettner, K. Ernestus, E. Stoelben, J. Wolf, P. Nürnberg, S. Perner, R. K. Thomas, Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2, 62ra93 (2010).
12. W. Pao, J. Chmielecki, Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10, 760-774 (2010).
13. E. L. Kwak, Y. J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, S. H. Ou, B. J. Dezube, P.A. Jänne,D. B. Costa, M.Varella-Garcia, W.H. Kim, T. J. Lynch, P. Fidias,H. Stubbs, J.A. Engelman, L. V. Sequist, W. Tan, L. Gandhi, M.Mino-Kenudson, G. C.Wei, S. M. Shreeve, M. J. Ratain, J. Settleman, J. G. Christensen, D. A. Haber, K. Wilner, R. Salgia, G. I. Shapiro, J. W. Clark, A. J. Iafrate, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
14. M. Meyerson, S. Gabriel, G. Getz, Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11, 685-696 (2010).
15. K. Bergethon, A. T. Shaw, S. H. Ou, R. Katayama, C. M. Lovly, N. T. McDonald, P. P. Massion, C. Siwak-Tapp, A. Gonzalez, R. Fang, E. J. Mark, J. M. Batten, H. Chen, K. D. Wilner, E. L. Kwak, J. W. Clark, D. P. Carbone, H. Ji, J. A. Engelman, M. Mino-Kenudson, W. Pao, A. J. Iafrate, ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863-870 (2012).
16. Y. S. Ju, W. C. Lee, J. Y. Shin, S. Lee, T. Bleazard, J. K. Won, Y. T. Kim, J. I. Kim, J. H. Kang, J. S. Seo, A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from wholegenome and transcriptome sequencing. Genome Res. 22, 436-445 (2012).
17. T. Kohno, H. Ichikawa, Y. Totoki, K. Yasuda, M. Hiramoto, T. Nammo, H. Sakamoto, K. Tsuta, K. Furuta, Y. Shimada, R. Iwakawa, H. Ogiwara, T. Oike, M. Enari, A. J. Schetter, H. Okayama, A. Haugen, V. Skaug, S. Chiku, I. Yamanaka, Y. Arai, S. Watanabe, I. Sekine, S. Ogawa, C. C. Harris, H. Tsuda, T. Yoshida, J. Yokota, T. Shibata, KIF5B-RET fusions in lung adenocarcinoma. Nat. Med. 18, 375-377 (2012).
18. D. Lipson,M. Capelletti, R. Yelensky, G. Otto, A. Parker, M. Jarosz, J. A. Curran, S. Balasubramanian, T. Bloom, K. W. Brennan, A. Donahue, S. R. Downing, G. M. Frampton, L. Garcia, F. Juhn, K. C. Mitchell, E. White, J. White, Z. Zwirko, T. Peretz, H. Nechushtan, L. Soussan-Gutman, J. Kim, H. Sasaki, H. R. Kim, S. I. Park, D. Ercan, C. E. Sheehan, J. S. Ross, M. T. Cronin, P. A. Jänne, P. J. Stephens, Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18, 382-384 (2012).
19. K. Takeuchi, M. Soda, Y. Togashi, R. Suzuki, S. Sakata, S. Hatano, R. Asaka, W. Hamanaka, H. Ninomiya, H. Uehara, Y. Lim Choi, Y. Satoh, S. Okumura, K. Nakagawa, H. Mano, Y. Ishikawa, RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 18, 378-381 (2012).
20. Cancer Genome Atlas Research Network, Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
21. M. Imielinski, A. H. Berger, P. S. Hammerman, B. Hernandez, T. J. Pugh, E. Hodis, J. Cho, J. Suh, M. Capelletti, A. Sivachenko, C. Sougnez, D. Auclair, M. S. Lawrence, P. Stojanov, K. Cibulskis, K. Choi, L. de Waal, T. Sharifnia, A. Brooks, H. Greulich, S. Banerji, T. Zander, D. Seidel, F. Leenders, S. Ansén, C. Ludwig, W. Engel-Riedel, E. Stoelben, J. Wolf, C. Goparju, K. Thompson, W. Winckler, D. Kwiatkowski, B. E. Johnson, P. A. Jänne, V. A. Miller, W. Pao, W. D. Travis, H. I. Pass, S. B. Gabriel, E. S. Lander, R. K. Thomas, L. A. Garraway, G. Getz, M. Meyerson, Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
22. J. Pardo, A. M. Martinez-Peñuela, J. J. Sola, A. Panizo, A. Gúrpide, J. M. Martinez-Peñuela, M. D. Lozano, Large cell carcinoma of the lung: An endangered species? Appl. Immunohistochem. Mol. Morphol. 17, 383-392 (2009).
23. N. Rekhtman, D. C. Ang, C. S. Sima, W. D. Travis, A. L. Moreira, Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod. Pathol. 24, 1348-1359 (2011).
24. M. Peifer, L. Fernández-Cuesta, M. L. Sos, J. George, D. Seidel, L. H. Kasper, D. Plenker, F. Leenders, R. Sun, T. Zander, R. Menon, M. Koker, I. Dahmen, C. Müller, V. Di Cerbo, H. U. Schildhaus, J. Altmüller, I. Baessmann, C. Becker, B. de Wilde, J. Vandesompele, D. Böhm, S. Ansén, F. Gabler, I. Wilkening, S. Heynck, J. M. Heuckmann, X. Lu, S. L. Carter, K. Cibulskis, S. Banerji, G. Getz, K. S. Park, D. Rauh, C. Grütter, M. Fischer, L. Pasqualucci, G. Wright, Z. Wainer, P. Russell, I. Petersen, Y. Chen, E. Stoelben, C. Ludwig, P. Schnabel, H. Hoffmann, T. Muley, M. Brockmann, W. Engel-Riedel, L. A. Muscarella, V. M. Fazio, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D. A. Heideman, P. J. Snijders, F. Cappuzzo, C. Ligorio, S. Damiani, J. Field, S. Solberg, O. T. Brustugun, M. Lund-Iversen, J. Sänger, J. H. Clement, A. Soltermann, H. Moch, W. Weder, B. Solomon, J. C. Soria, P. Validire, B. Besse, E. Brambilla, C. Brambilla, S. Lantuejoul, P. Lorimier, P. M. Schneider, M. Hallek, W. Pao, M. Meyerson, J. Sage, J. Shendure, R. Schneider, R. Büttner, J. Wolf, P. Nürnberg, S. Perner, L. C. Heukamp, P. K. Brindle, S. Haas, R. K. Thomas, Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44, 1104-1110 (2012).
25. C. M. Rudin, S. Durinck, E. W. Stawiski, J. T. Poirier, Z. Modrusan, D. S. Shames, E. A. Bergbower, Y. Guan, J. Shin, J. Guillory, C. S. Rivers, C. K. Foo, D. Bhatt, J. Stinson, F. Gnad, P. M. Haverty, R. Gentleman, S. Chaudhuri, V. Janakiraman, B. S. Jaiswal, C. Parikh, W. Yuan, Z. Zhang, H. Koeppen, T. D.Wu, H. M. Stern, R. L. Yauch, K. E. Huffman, D. D. Paskulin, P. B. Illei, M. Varella-Garcia, A. F. Gazdar, F. J. de Sauvage, R. Bourgon, J. D. Minna, M. V. Brock, S. Seshagiri, Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44, 1111-1116 (2012).
26. S. L. Carter, K. Cibulskis, E. Helman, A. McKenna, H. Shen, T. Zack, P. W. Laird, R. C. Onofrio, W. Winckler, B. A. Weir, R. Beroukhim, D. Pellman, D. A. Levine, E. S. Lander, M. Meyerson, G. Getz, Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
27. R. Iwakawa, T. Kohno, Y. Anami, M. Noguchi, K. Suzuki, Y. Matsuno, K. Mishima, R. Nishikawa, F. Tashiro, J. Yokota, Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma. Clin. Cancer Res. 14, 3746-3753 (2008).
28. L. Ding, G. Getz, D. A. Wheeler, E. R. Mardis, M. D. McLellan, K. Cibulskis, C. Sougnez, H. Greulich, D. M. Muzny, M. B. Morgan, L. Fulton, R. S. Fulton, Q. Zhang, M. C. Wendl, M. S. Lawrence, D. E. Larson, K. Chen, D. J. Dooling, A. Sabo, A. C. Hawes, H. Shen, S. N. Jhangiani, L. R. Lewis, O. Hall, Y. Zhu, T. Mathew, Y. Ren, J. Yao, S. E. Scherer, K. Clerc, G. A. Metcalf, B. Ng, A. Milosavljevic, M. L. Gonzalez-Garay, J. R. Osborne, R. Meyer, X. Shi, Y. Tang, D. C. Koboldt, L. Lin, R. Abbott, T. L. Miner, C. Pohl, G. Fewell, C. Haipek, H. Schmidt, B. H. Dunford-Shore, A. Kraja, S. D. Crosby, C. S. Sawyer, T. Vickery, S. Sander, J. Robinson, W. Winckler, J. Baldwin, L. R. Chirieac, A. Dutt, T. Fennell, M. Hanna, B. E. Johnson, R. C. Onofrio, R. K. Thomas, G. Tonon, B. A. Weir, X. Zhao, L. Ziaugra, M. C. Zody, T. Giordano, M. B. Orringer, J. A. Roth, M. R. Spitz, I. I. Wistuba, B. Ozenberger, P. J. Good, A. C. Chang, D. G. Beer, M. A. Watson, M. Ladanyi, S. Broderick, A. Yoshizawa, W. D. Travis, W. Pao, M. A. Province, G. M. Weinstock, H. E. Varmus, S. B. Gabriel, E. S. Lander, R. A. Gibbs, M. Meyerson, R. K. Wilson, Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
29. D. Malhotra, E. Portales-Casamar, A. Singh, S. Srivastava, D. Arenillas, C. Happel, C. Shyr, N. Wakabayashi, T. W. Kensler, W. W. Wasserman, S. Biswal, Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 38, 5718-5734 (2010).
30. Y. R. Kim, J. E. Oh, M. S. Kim, M. R. Kang, S. W. Park, J. Y. Han, H. S. Eom, N. J. Yoo, S. H. Lee, Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J. Pathol. 220, 446-451 (2010).
31. T. Shibata, T. Ohta, K. I. Tong, A. Kokubu, R. Odogawa, K. Tsuta, H. Asamura, M. Yamamoto, S. Hirohashi, Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. U.S.A. 105, 13568-13573 (2008).
32. T. Ohta, K. Iijima, M. Miyamoto, I. Nakahara, H. Tanaka, M. Ohtsuji, T. Suzuki, A. Kobayashi, J. Yokota, T. Sakiyama, T. Shibata, M. Yamamoto, S. Hirohashi, Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 68, 1303-1309 (2008).
33. D. Cappellen, C. De Oliveira, D. Ricol, S. de Medina, J. Bourdin, X. Sastre-Garau, D. Chopin, J. P. Thiery, F. Radvanyi, Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23, 18-20 (1999).
34. M. Karoui, H. Hofmann-Radvanyi, U. Zimmermann, A. Couvelard, C. Degott, L. Faridoni-Laurens, J. C. Ahomadegbe, S. Gazzeri, E. Brambilla, T. Clerici, P. Charbonnier, C. Tresallet, E. Mitry, C. Penna, P. Rougier, C. Boileau, J. P. Thiery, B. Nordlinger, B. Franc, F. Radvanyi, No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene 20, 5059-5061 (2001).
35. A. Dutt, H. B. Salvesen, T. H. Chen, A. H. Ramos, R. C. Onofrio, C. Hatton, R. Nicoletti, W.Winckler, R. Grewal, M. Hanna, N. Wyhs, L. Ziaugra, D. J. Richter, J. Trovik, I. B. Engelsen, I. M. Stefansson, T. Fennell, K. Cibulskis, M. C. Zody, L. A. Akslen, S. Gabriel, K. K. Wong, W. R. Sellers, M.Meyerson, H. Greulich, Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. U.S.A. 105, 8713-8717 (2008).
36. J. S. Seo, Y. S. Ju, W. C. Lee, J. Y. Shin, J. K. Lee, T. Bleazard, J. Lee, Y. J. Jung, J. O. Kim, J. Y. Shin, S. B. Yu, J. Kim, E. R. Lee, C. H. Kang, I. K. Park, H. Rhee, S. H. Lee, J. I. Kim, J. H. Kang, Y. T. Kim, The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 22, 2109-2119 (2012).
37. B. A. Weir, M. S. Woo, G. Getz, S. Perner, L. Ding, R. Beroukhim, W. M. Lin, M. A. Province, A. Kraja, L. A. Johnson, K. Shah, M. Sato, R. K. Thomas, J. A. Barletta, I. B. Borecki, S. Broderick, A. C. Chang, D. Y. Chiang, L. R. Chirieac, J. Cho, Y. Fujii, A. F. Gazdar, T. Giordano, H. Greulich, M. Hanna, B. E. Johnson, M. G. Kris, A. Lash, L. Lin, N. Lindeman, E. R. Mardis, J. D. McPherson, J. D. Minna, M. B. Morgan, M. Nadel, M. B. Orringer, J. R. Osborne, B. Ozenberger, A. H. Ramos, J. Robinson, J. A. Roth, V. Rusch, H. Sasaki, F. Shepherd, C. Sougnez, M. R. Spitz, M. S. Tsao, D. Twomey, R. G. Verhaak, G. M. Weinstock, D. A. Wheeler, W. Winckler, A. Yoshizawa, S. Yu, M. F. Zakowski, Q. Zhang, D. G. Beer, I. I. Wistuba, M. A. Watson, L. A. Garraway, M. Ladanyi, W. D. Travis,W. Pao, M. A. Rubin, S. B. Gabriel, R. A. Gibbs, H. E. Varmus, R. K. Wilson, E. S. Lander, M. Meyerson, Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893-898 (2007).
38. R. K. Thomas, A. C. Baker, R. M. Debiasi, W. Winckler, T. Laframboise, W. M. Lin, M. Wang, W. Feng, T. Zander, L. MacConaill, J. C. Lee, R. Nicoletti, C. Hatton, M. Goyette, L. Girard, K. Majmudar, L. Ziaugra, K. K. Wong, S. Gabriel, R. Beroukhim, M. Peyton, J. Barretina, A. Dutt, C. Emery, H. Greulich, K. Shah, H. Sasaki, A. Gazdar, J. Minna, S. A. Armstrong, I. K. Mellinghoff, F. S. Hodi, G. Dranoff, P. S. Mischel, T. F. Cloughesy, S. F. Nelson, L. M. Liau, K. Mertz, M. A. Rubin, H. Moch, M. Loda, W. Catalona, J. Fletcher, S. Signoretti, F. Kaye, K. C. Anderson, G. D. Demetri, R. Dummer, S. Wagner, M. Herlyn, W. R. Sellers, M. Meyerson, L. A. Garraway, High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347-351 (2007).
39. F. Su, A. Viros, C. Milagre, K. Trunzer, G. Bollag, O. Spleiss, J. S. Reis-Filho, X. Kong, R. C. Koya, K. T. Flaherty, P. B. Chapman, M. J. Kim, R. Hayward, M. Martin, H. Yang, Q. Wang, H. Hilton, J. S. Hang, J. Noe, M. Lambros, F. Geyer, N. Dhomen, I. Niculescu-Duvaz, A. Zambon, D. Niculescu-Duvaz, N. Preece, L. Robert, N. J. Otte, S. Mok, D. Kee, Y. Ma, C. Zhang, G. Habets, E. A. Burton, B. Wong, H. Nguyen, M. Kockx, L. Andries, B. Lestini, K. B. Nolop, R. J. Lee, A. K. Joe, J. L. Troy, R. Gonzalez, T. E. Hutson, I. Puzanov, B. Chmielowski, C. J. Springer, G. A. McArthur, J. A. Sosman, R. S. Lo, A. Ribas, R. Marais, RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215 (2012).
40. F. Cappuzzo, F. R. Hirsch, E. Rossi, S. Bartolini, G. L. Ceresoli, L. Bemis, J. Haney, S. Witta, K. Danenberg, I. Domenichini, V. Ludovini, E. Magrini, V. Gregorc, C. Doglioni, A. Sidoni, M. Tonato, W. A. Franklin, L. Crino, P. A. Bunn Jr., M. Varella-Garcia, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97, 643-655 (2005).
41. M. S. Tsao, A. Sakurada, J. C. Cutz, C. Q. Zhu, S. Kamel-Reid, J. Squire, I. Lorimer, T. Zhang, N. Liu, M. Daneshmand, P. Marrano, G. da Cunha Santos, A. Lagarde, F. Richardson, L. Seymour, M. Whitehead, K. Ding, J. Pater, F. A. Shepherd, Erlotinib in lung cancer-Molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144 (2005).
42. M. Fukuoka, Y. L. Wu, S. Thongprasert, P. Sunpaweravong, S. S. Leong, V. Sriuranpong, T. Y. Chao, K. Nakagawa, D. T. Chu, N. Saijo, E. L. Duffield, Y. Rukazenkov, G. Speake, H. Jiang, A. A. Armour, K. F. To, J. C. Yang, T. S. Mok, Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/ paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29, 2866-2874 (2011).
43. I. K.Mellinghoff, M. Y.Wang, I. Vivanco, D. A. Haas-Kogan, S. Zhu, E. Q. Dia, K. V. Lu, K. Yoshimoto, J. H. Huang, D. J. Chute, B. L. Riggs, S. Horvath, L. M. Liau, W. K. Cavenee, P. N. Rao, R. Beroukhim, T. C. Peck, J. C. Lee, W. R. Sellers, D. Stokoe, M. Prados, T. F. Cloughesy, C. L. Sawyers, P. S. Mischel, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005).
44. M. L. Sos, M. Koker, B. A. Weir, S. Heynck, R. Rabinovsky, T. Zander, J. M. Seeger, J. Weiss, F. Fischer, P. Frommolt, K. Michel, M. Peifer, C. Mermel, L. Girard, M. Peyton, A. F. Gazdar, J. D. Minna, L. A. Garraway, H. Kashkar, W. Pao, M. Meyerson, R. K. Thomas, PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 69, 3256-3261 (2009).
45. M.D. Wilkerson, X. Yin, V.Walter,N. Zhao, C. R. Cabanski, M. C.Hayward, C. R. Miller, M.A. Socinski, A. M. Parsons, L. B. Thorne, B. E. Haithcock, N. K. Veeramachaneni, W. K. Funkhouser, S. H. Randell, P. S. Bernard, C. M. Perou, D. N. Hayes, Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS One 7, e36530 (2012).
46. M. D. Wilkerson, X. Yin, K. A. Hoadley, Y. Liu,M. C. Hayward, C. R. Cabanski, K.Muldrew, C. R. Miller, S. H. Randell, M. A. Socinski, A. M. Parsons, W. K. Funkhouser, C. B. Lee, P. J. Roberts, L. Thorne, P. S. Bernard, C. M. Perou, D. N. Hayes, Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin. Cancer Res. 16, 4864-4875 (2010).
47. R. Shen, A. B. Olshen, M. Ladanyi, Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics 25, 2906-2912 (2009).
48. H. Greulich, B. Kaplan, P.Mertins, T. H. Chen, K. E. Tanaka, C. H. Yun, X. Zhang, S. H. Lee, J. Cho, L. Ambrogio, R. Liao, M. Imielinski, S. Banerji, A. H. Berger, M. S. Lawrence, J. Zhang, N. H. Pho, S. R. Walker, W. Winckler, G. Getz, D. Frank, W. C. Hahn, M. J. Eck, D. R. Mani, J. D. Jaffe, S. A. Carr, K. K. Wong, M. Meyerson, Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc. Natl. Acad. Sci. U.S.A. 109, 14476-14481 (2012).
49. K. B. Dahlman, J. Xia, K. Hutchinson, C. Ng, D. Hucks, P. Jia, M. Atefi, Z. Su, S. Branch, P. L. Lyle, D. J. Hicks, V. Bozon, J. A. Glaspy, N. Rosen, D. B. Solit, J. L. Netterville, C. L. Vnencak-Jones, J. A. Sosman, A. Ribas, Z. Zhao, W. Pao, BRAFL597 mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2, 791-797 (2012).
50. P. T. Wan, M. J. Garnett, S. M. Roe, S. Lee, D. Niculescu-Duvaz, V. M. Good, C. M. Jones, C. J. Marshall, C. J. Springer, D. Barford, R. Marais; Cancer Genome Project, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
51. S. J. Heidorn, C. Milagre, S. Whittaker, A. Nourry, I. Niculescu-Duvas, N. Dhomen, J. Hussain, J. S. Reis-Filho, C. J. Springer, C. Pritchard, R. Marais, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
52. B. Sen, S. Peng, X. Tang, H. S. Erickson, H. Galindo, T. Mazumdar, D. J. Stewart, I. Wistuba, F. M. Johnson, Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci. Transl. Med. 4, 136ra70 (2012).
53. R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B.Massuti, E. Felip, R. Palmero, R. Garcia-Gomez, C. Pallares, J. M. Sanchez, R. Porta, M. Cobo, P. Garrido, F. Longo, T. Moran, A. Insa, F. De Marinis, R. Corre, I. Bover, A. Illiano, E. Dansin, J. de Castro, M. Milella, N. Reguart, G. Altavilla, U. Jimenez, M. Provencio,M. A. Moreno, J. Terrasa, J. Muñoz-Langa, J. Valdivia,D. Isla,M. Domine, O.Molinier, J.Mazieres, N. Baize, R. Garcia-Campelo, G. Robinet, D. Rodriguez-Abreu, G. Lopez-Vivanco, V. Gebbia, L. Ferrera-Delgado, P. Bombaron, R. Bernabe, A. Bearz, A. Artal, E. Cortesi, C. Rolfo, M. Sanchez-Ronco, A. Drozdowskyj, C. Queralt, I. de Aguirre, J. L. Ramirez, J. J. Sanchez, M. A. Molina, M. Taron, L. Paz-Ares, Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo- Cancérologie and Associazione Italiana Oncologia Toracica, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-celllung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239-246 (2012).
54. A. T. Shaw, D. W. Kim, K. Nakagawa, T. Seto, L. Crinó, M. J. Ahn, T. De Pas, B. Besse, B. J. Solomon, F. Blackhall, Y. L. Wu, M. Thomas, K. J. O'Byrne, D. Moro-Sibilot, D. R. Camidge, T. Mok, V. Hirsh, G. J. Riely, S. Iyer, V. Tassell, A. Polli, K. D. Wilner, P. A. Jänne, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394 (2013).
55. C. Greenman, P. Stephens, R. Smith, G. L. Dalgliesh, C. Hunter, G. Bignell, H. Davies, J. Teague, A. Butler, C. Stevens, S. Edkins, S. O'Meara, I. Vastrik, E. E. Schmidt, T. Avis, S. Barthorpe, G. Bhamra, G. Buck, B. Choudhury, J. Clements, J. Cole, E. Dicks, S. Forbes, K. Gray, K. Halliday, R. Harrison, K. Hills, J. Hinton, A. Jenkinson, D. Jones, A. Menzies, T. Mironenko, J. Perry, K. Raine, D. Richardson, R. Shepherd, A. Small, C. Tofts, J. Varian, T. Webb, S. West, S. Widaa, A. Yates, D. P. Cahill, D. N. Louis, P. Goldstraw, A. G. Nicholson, F. Brasseur, L. Looijenga, B. L. Weber, Y. E. Chiew, A. DeFazio, M. F. Greaves, A. R. Green, P. Campbell, E. Birney, D. F. Easton, G. Chenevix-Trench, M. H. Tan, S. K. Khoo, B. T. Teh, S. T. Yuen, S. Y. Leung, R. Wooster, P. A. Futreal, M. R. Stratton, Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
56. J. T. Ney, S. Froehner, A. Roesler, R. Buettner, S. Merkelbach-Bruse, High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS, BRAF, PIK3CA, and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. Arch. Pathol. Lab. Med. 136, 983-992 (2012).
57. S. Querings, J. Altmüller, S. Ansén, T. Zander, D. Seidel, F. Gabler, M. Peifer, E. Markert, K. Stemshorn, B. Timmermann, B. Saal, S. Klose, K. Ernestus, M. Scheffler, W. Engel-Riedel, E. Stoelben, E. Brambilla, J. Wolf, P. Nürnberg, R. K. Thomas, Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 6, e19601 (2011).
58. F. Göke, S. Perner, Translational research and diagnostics in lung cancer. Pathologe 33, (Suppl. 2), 269-272 (2012).
59. H. U. Schildhaus, L. C. Heukamp, S.Merkelbach-Bruse, K. Riesner, K. Schmitz, E. Binot, E. Paggen, K. Albus, W. Schulte, Y. D. Ko, A. Schlesinger, S. Ansén, W. Engel-Riedel, M. Brockmann, M. Serke, U. Gerigk, S. Huss, F. Göke, S. Perner, K. Hekmat, K. F. Frank, M. Reiser, R. Schnell, M. Bos, C.Mattonet,M. Sos, E. Stoelben, J.Wolf, T. Zander, R. Buettner, Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod. Pathol. 25, 1473-1480 (2012).
60. S. Perner, P. L. Wagner, F. Demichelis, R. Mehra, C. J. Lafargue, B. J. Moss, S. Arbogast, A. Soltermann, W. Weder, T. J. Giordano, D. G. Beer, D. S. Rickman, A. M. Chinnaiyan, H. Moch, M. A. Rubin, EML4-ALK fusion lung cancer: A rare acquired event. Neoplasia 10, 298-302 (2008).
61. S. Perner, F. Demichelis, R. Beroukhim, F. H. Schmidt, J. M. Mosquera, S. Setlur, J. Tchinda, S. A. Tomlins, M. D. Hofer, K. G. Pienta, R. Kuefer, R. Vessella, X. W. Sun, M. Meyerson, C. Lee, W. R. Sellers, A. M. Chinnaiyan, M. A. Rubin, TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337-8341 (2006).
62. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P.Mesirov,Gene set enrichment analysis: A knowledgebased approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550 (2005).